Proteomics and Dimerix partner to improve the treatment of kidney disease

Medical technology company Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ), a leader in providing predictive diagnostics, is pleased to announce that it has partnered with innovative drug developer Dimerix Limited (ASX:DXB) to improve the treatment of chronic kidney disease (CKD).

Media Release


  • This field is for validation purposes and should be left unchanged.